| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.03 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.03 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | -0.34 | 0.03 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.04 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.062 | 0.04 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.04 |